The American Society of Bone and Mineral Research annual conference was held at the Colorado Convention Center, Denver, Colorado, on September 8th to 11th.
The ASBMR Annual Meeting is the world’s largest and most diverse meeting in the bone, mineral and musculoskeletal research field, attracting more than 4,000 attendees from more than 70 countries, including clinicians and researchers, representing all career levels and specializing in a variety of disciplines.
The Jansen’s Foundation’s research team from Boston Massachusetts Hospital and Harvard medical school presented two posters and three oral presentations on Jansen’s Disease, and The Jansen’s Foundation was honored to be a guest at this prestigious event.
The presentations and posters were very well received! The science of the inverse-agonist used to stop or inhibit the overactive PTH receptor has been tested in mice with promising results. Not only has the Jansen’s mice bone shown increase in quality, but surprisingly they have also increased in length.
The promising results lead us to believe that we are on the threshold of the first clinical trial to test these new inverse agonists on humans.
TJF’s Dream Team!
Back Row, Dr. Harald Jueppner, MGH; Dr. Sihoon Lee, Professor from Korea studying PTH-related diseases; Dr. Michael Mannstadt, Chief of Endocrine Unit MGH; Hiroshi Saito; Dr. Thomas Gardella, MGH.
Front: Dr. Hiroshi Noda, MGH Endocrine Unit, performed and presented studies in Jansen Mice reported at 2017.
Another magical picture from the American Society for Bone and Mineral Research Conference.
L-R, Dr. Larry Suva, co-discover of PTHrP, currently a Professor at the Univ. of Texas; Dr. Harald Juepnner at MGH; Prof. Jack Martin, co-discover of PTHrP, currently at Univ. Melbourne; Dr. John T. Potts, first to report sequence structure and chemical synthesis of PTH; Dr. Hiroshi Saito, clinical fellow studying natural history of Jansen’s with Dr. Jueppner at MGH.
The conference was a wonderful learning experience and an amazing opportunity to meet some of the great minds behind the science of medical cures and revolutionary therapies.
Dr. Ernestina Schipani, the lead scientist along with Dr. Harald Jueppner at the MGH on the first discovery of a Jansen's Mutation (H223R) reported in Science! Their efforts were published in a research paper in 1995! She is currently a Professor at the University of Michigan. Pictured here with Neena Nizar.
Today, there is no question that the patient voice is growing in prominence with the advancement of cures. With the emphasis we see today on accumulating real-world evidence and prioritizing patient-focused drug development, the patient voice and perspective has become invaluable.
It was an honor and a powerful moment for the Jansen's Foundation to be invited to such an amazing evening and share in the gathering of incredible minds.
It is remarkable the advancements in science, and the passion for treatments and cures. The road ahead is certainly full of hope!